Umit Bey retweeted
We generate data even while we sleep.
This data is extremely valuable.
But right now, most of the time it doesn’t belong to us.
Science’s latest investigation showed this once again.
This is changing.
MATRIX is turning sleep and EEG data into a #RWA and preparing to tokenize it.
You own it. You decide. You earn.
Replying to @MatrixAINetwork
For readers who want to verify the reporting:
1. Original investigation — Science:
science.org/content/article/…
2. Additional reporting — Tom's Hardware, November 9, 2026:
tomshardware.com/peripherals…
The investigation was conducted by Science with the Pulitzer Center's AI Accountability Network.
Umit Bey retweeted
Your brainwaves might be helping train AI.
And you probably didn't buy your EEG device thinking you'd become part of someone's AI training dataset.
A recent investigation reported that around 50,000 hours of EEG recordings from Muse users had been used to train an AI model.
The issue? The company's earlier privacy policy had not explicitly disclosed that brain recordings could be used to train foundation models. The company later updated its policy and said identifying information was removed.
We're moving into an era where human biology is not just something we measure. It's something AI can learn from.
So here's a question worth asking:
When your body generates valuable data, who gets to decide what happens to it?
#AI #MatrixAINetwork
Umit Bey retweeted
In this October AMA, CEO Owen Tao addresses community questions covering:
Exchange challenges: The impact of delistings and the wider exchange landscape.
Mainnet migration: Technical progress, exchange coordination and the possibility of a more gradual transition.
Liquidity and funding: The current challenges and efforts to explore external partnerships and investment.
RWA standards: The status of Matrix's involvement in the CMCA standards work.
Mainnet readiness: Five areas covering security, asset migration, nodes, ecosystem tooling and testnet stability.
BioData quality: Source verification, algorithmic assessment and researcher feedback.
Data security and privacy: Distributed storage, usage rights, privacy-conscious processing and different regulatory environments.
Ecosystem adoption: Institutional data partnerships and user-generated BioData.
This is not a conversation pretending that everything is easy.
Some challenges remain. Some work is progressing. Some ambitions still need to be demonstrated.
But the work continues, and the community deserves to hear the discussion directly.
Watch the full October AMA and join the conversation.
The market has been frightening enough lately. So, for October's AMA, we decided to make Halloween official. 🎃
Behind the costumes, though, were some very real questions.
Exchange delistings. Market conditions. Liquidity and funding. Mainnet migration. BioData quality, security and privacy.
We won't pretend everything is easy, or that every challenge has been resolved.
But difficult times are also when a team needs to keep thinking, building and finding a way forward.
This October AMA is a conversation about where Matrix stands, what we're working through, and what comes next.
Let's bring some energy back to the community. What would you most like to see Matrix deliver next?
#MatrixAINetwork #BioData
Umit Bey retweeted
A BioData RWA ecosystem needs actual data and actual users.
In the October AMA, the team discussed two routes:
Working with institutions that may contribute existing datasets, and opening the network for individuals to upload their own data.
The initial ambition discussed was to reach hundreds of thousands of user-level records.
That is a target, not an achievement. But it raises the right question:
What would make institutions and individuals willing to contribute meaningful BioData?
#MatrixAINetwork #RWA
The market has been frightening enough lately. So, for October's AMA, we decided to make Halloween official. 🎃
Behind the costumes, though, were some very real questions.
Exchange delistings. Market conditions. Liquidity and funding. Mainnet migration. BioData quality, security and privacy.
We won't pretend everything is easy, or that every challenge has been resolved.
But difficult times are also when a team needs to keep thinking, building and finding a way forward.
This October AMA is a conversation about where Matrix stands, what we're working through, and what comes next.
Let's bring some energy back to the community. What would you most like to see Matrix deliver next?
#MatrixAINetwork #BioData
Umit Bey retweeted
Human BioData is not ordinary data.
In the October AMA, Owen discussed separating data ownership rights from usage rights, distributed storage, removing private information and processing data differently depending on regulatory requirements.
One particularly interesting direction: in stricter environments, processing may happen on the user's device, with only selected characteristic values or results retrieved.
The original data does not always need to travel for its value to be useful.
How should the industry balance data utility with personal privacy?
#MatrixAINetwork #DataPrivacy
The market has been frightening enough lately. So, for October's AMA, we decided to make Halloween official. 🎃
Behind the costumes, though, were some very real questions.
Exchange delistings. Market conditions. Liquidity and funding. Mainnet migration. BioData quality, security and privacy.
We won't pretend everything is easy, or that every challenge has been resolved.
But difficult times are also when a team needs to keep thinking, building and finding a way forward.
This October AMA is a conversation about where Matrix stands, what we're working through, and what comes next.
Let's bring some energy back to the community. What would you most like to see Matrix deliver next?
#MatrixAINetwork #BioData
Umit Bey retweeted
More data does not automatically mean better data.
In the October AMA, Matrix described three layers for assessing BioData quality:
• Identifying where the data comes from, including verified hardware sources.
• Using algorithms to detect inconsistencies and abnormal patterns.
• Allowing researchers and users to evaluate the data's usefulness.
Why does this matter?
Because BioData intended for real-world use needs more than volume. It needs credibility.
What would make you trust a BioData record?
#MatrixAINetwork #BioData
🤖 Made with AI
The market has been frightening enough lately. So, for October's AMA, we decided to make Halloween official. 🎃
Behind the costumes, though, were some very real questions.
Exchange delistings. Market conditions. Liquidity and funding. Mainnet migration. BioData quality, security and privacy.
We won't pretend everything is easy, or that every challenge has been resolved.
But difficult times are also when a team needs to keep thinking, building and finding a way forward.
This October AMA is a conversation about where Matrix stands, what we're working through, and what comes next.
Let's bring some energy back to the community. What would you most like to see Matrix deliver next?
#MatrixAINetwork #BioData
Umit Bey retweeted
A new mainnet needs more than working code.
In the October AMA, the team outlined five areas of preparation:
Security and code integrity
Ledger and asset-swap logistics
Validator and node infrastructure
Ecosystem tools and integrations
Testnet stability and benchmarks
The testnet had already been running for almost three months at the time of the AMA.
Building infrastructure means preparing for what can go wrong, not just demonstrating what can work.
Which of these five areas deserves the most attention?
#MatrixAINetwork #EVM
Umit Bey retweeted
Replying to @MatrixAINetwork
It’s commendable that you’re open to discussing this and willing to address it directly. This is a topic most projects prefer to avoid. I agree that a project’s long-term future shouldn’t depend solely on CEX listings, but being listed on centralized exchanges is still important for reaching a broader audience. Right now, Gate is our only CEX listing and it remains necessary and valuable for the project. At the same time, activating the DEX would provide much-needed support. I don’t think a project should exist entirely without any CEX presence, the two serve different types of users. Given the current situation, focusing on a single CEX is better for liquidity management. Ultimately, the goal shouldn’t be choosing one over the other, but building a sustainable ecosystem that leverages the strengths of both.
Umit Bey retweeted
Let's address the uncomfortable subject.
The October AMA included a direct question about Matrix following its delisting from KuCoin and MEXC.
The conversation acknowledged the concern and discussed the wider exchange landscape, including other exchange channels and the DEX direction.
A delisting is serious. It affects confidence, access and liquidity. Pretending otherwise helps nobody.
But should the future of a blockchain project be judged by its exchange listings alone?
#MatrixAINetwork #Crypto
The market has been frightening enough lately. So, for October's AMA, we decided to make Halloween official. 🎃
Behind the costumes, though, were some very real questions.
Exchange delistings. Market conditions. Liquidity and funding. Mainnet migration. BioData quality, security and privacy.
We won't pretend everything is easy, or that every challenge has been resolved.
But difficult times are also when a team needs to keep thinking, building and finding a way forward.
This October AMA is a conversation about where Matrix stands, what we're working through, and what comes next.
Let's bring some energy back to the community. What would you most like to see Matrix deliver next?
#MatrixAINetwork #BioData
Umit Bey retweeted
The AI trade is being asked a brutal question: where is the return on all that spending?
There’s another question the industry hasn’t answered nearly as well:
Who can prove the data going into these models is what they claim to be?
A bigger model can amplify good data. It can also amplify bad assumptions.
Which is the more underrated AI bottleneck: compute or evidence?
#MatrixAINetwork #AI
Umit Bey retweeted
I won't pretend nine years never made me doubt this.
There were stretches where the price fell, the market looked elsewhere, and the quiet question sat there: what if I'm just wrong? Any honest founder has felt it.
What kept me in wasn't blind faith. It was going back to the actual problem, who owns the data your body makes, and finding it still unsolved, still mattering more each year. The doubt never won because the problem never went away.
Umit Bey retweeted
Drug discovery AI models are only as good as the data they train on.
High-quality, consented, attributable biological datasets are therefore a strategic asset.
Almost none of that strategic asset currently lives on open, verifiable rails.
#BioDataRWA
Your health data is the oil of the 21st century, yet most of it sits in hospital silos.
Tokenize usage rights under privacy tech and individuals can finally capture value instead of just generating it.
#BioDataRWA
Umit Bey retweeted
Every person generates biological data every day.
Very few of them have any claim on the economic value that data creates downstream.
Closing that gap is both a technical and a coordination problem.
#BioDataRWA
Institutions already spend heavily to access or generate biological datasets.
They just do it through slow, exclusive, and opaque contracts.
A standardized, privacy-preserving market for the same data would be faster and more efficient for everyone involved.
#BiodataRWA
Umit Bey retweeted
Here’s a design decision I’m proud of, in plain terms.
We built the new Matrix chain so that every time someone uploads their biodata, a small amount of MAN is destroyed. Permanently. Written into the protocol, not a policy anyone can reverse.
Most tokens quietly print more of themselves. We built one that gets scarcer the more it’s actually used. I wanted the token’s health tied to real usage, not to my promises. Promises are cheap, and I’ve watched too many of them break.
Umit Bey retweeted
Institutions already spend heavily to access or generate biological datasets.
They just do it through slow, exclusive, and opaque contracts.
A standardized, privacy-preserving market for the same data would be faster and more efficient for everyone involved.
#BiodataRWA
A single new drug still costs over $2 billion and takes a decade. Most of the useful data created along the way stays locked in silos.
What if that data itself could become a liquid, attributable asset while remaining private?
#BioDataRWA
Umit Bey retweeted
Your health data is the oil of the 21st century, yet most of it sits in hospital silos.
Tokenize usage rights under privacy tech and individuals can finally capture value instead of just generating it.
#BioDataRWA
A new drug costs ~$2.3B and takes 10–15 years. 90% fail. Most capital only arrives after Phase II. This is the Valley of Death.
#RWA will lets early pipelines tokenize future revenue rights and pull global capital in much earlier.
#BioDataRWA
Umit Bey retweeted
Mainland China largely blocks domestic RWA issuance. Hong Kong does not.
That regulatory gap has turned Hong Kong into a testing ground for Chinese biotech assets. Future revenue rights, equipment ownership, and clinical-stage claims are all being experimented with under clearer rules.
The experiments are small. The signal is large.
#BioDataRWA
Bio-data tokenization still sounds like a distant theory to many since it hasn't caught up with traditional RWAs yet. I get it.
While most markets are still debating the theory, a few Chinese biotech pioneers are already testing it in practice:
• One firm tokenized the future revenue rights of its GLP-1 pipeline via a Hong Kong structure.
• Another put thousands of diagnostic devices on-chain to unlock liquidity.
These are early, imperfect experiments, but they prove the concept is officially shifting into real capital formation.
#BioDataRWA
Umit Bey retweeted
Most RWA projects today are wrapping things that already trade.
Biological data is different. It is generated constantly, it has clear institutional buyers, and almost none of it is currently liquid.
That gap is the opportunity.
#BioDataRWA
Biotech holds massive value, but it’s completely illiquid.
RWA tokenization bridges this gap, unlocking liquidity for real-world bio-data and research assets.
#BioDataRWA
Umit Bey retweeted
I think a lot about the people who held through nine years of this.
Not the ones chasing the next thing. The ones who read the actual thesis, understood what we were building, and decided it was worth waiting for. Some of them I've never met. Some have been in our channels longer than some of my employees.
Whatever Matrix becomes, it exists because they didn't leave. I don't forget that.
Umit Bey retweeted
Bio-data tokenization still sounds like a distant theory to many since it hasn't caught up with traditional RWAs yet. I get it.
While most markets are still debating the theory, a few Chinese biotech pioneers are already testing it in practice:
• One firm tokenized the future revenue rights of its GLP-1 pipeline via a Hong Kong structure.
• Another put thousands of diagnostic devices on-chain to unlock liquidity.
These are early, imperfect experiments, but they prove the concept is officially shifting into real capital formation.
#BioDataRWA
When I tweet about Bio-Data RWA, I know it sounds crazy to most people 😅
But that's how every major shift happens:
First it's dismissed, then it's debated, and finally everyone acts like they saw it coming all along.
Real innovation always feels like fiction before it becomes the standard.
#RWA
















